抗肝癌中藥物質(zhì)基礎(chǔ)研究進(jìn)展

中圖分類(lèi)號(hào)：R979.1 文獻(xiàn)標(biāo)識(shí)碼：A 文章編號(hào)：1001-8751（2025）03-0145-09

AdvancesintheBasicResearchofTraditionalChineseMedicine forAnti-LiverCancer

LiuLu-yang1，WuSi-yang1，ZhaoLi-feng1，YuXin1，ChengXue-haol，Huang Zhi-shan12，Yuan Zhengl，LiYing-feil （1 Institute of Chinese Materia Medica China Academy of Chinese Medical Sciences，Beijing 100700; 2BeijingUniversity of Traditional Chinese Medicine， Beijing 102488）

Abstract： Primary liver cancer poses a serious threat to human health，and traditional Chinese medicine （TCM） has a long historyinthe preventionand treatment of primary livercancer.In recent years，its therapeutic mechanisms havealso atracted atention.Inaddition todiscussing the material basis of Chinese medicine substances by mechanismofaction，such asaffecting thecellcycle，inducingapoptosis and autophagy，inhibitingangiogenesis and metastasis，microenvironment regeneration，DNA methylation，and regulating immuneresponses，this article summarizes common Chinese medicine substances used in the treatment of primary liver cancer，such as matrine， berberine，and curcumin，among others.Traditional Chinese medicine has a protective and conditioning effect on patients with long-term primary liver cancer. Promoting research on Chinese medicine and its mechanisms of action is crucial for the treatment of primary liver cancer.The purposeof this study is to supportTCMresearch and clinical application while offering a scientific foundation for its use in the treatment of primary liver cancer.

Key words： traditional Chinese medicine；liver cancer；material basis;mechanism of action;acutophagy angiogenesis Inhibition

原發(fā)性肝癌（Primary liver cancer，PLC），亦稱肝細(xì)胞癌（Hepatocellularcarcinoma，HCC），在全球惡性腫瘤中占有一席之地，其中中國(guó)過(guò)去曾占全球肝癌負(fù)擔(dān)的一半以上，但最近觀察到全國(guó)性肝癌發(fā)病率的下降[I。（剩余21368字）